Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Clinical trial NCT04767308 · UNKNOWN

Trial details

NCT number: NCT04767308
Sponsor: Huazhong University of Science and Technology
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

CD5+ Relapsed/Refractory Hematopoietic Malignancies Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Peripheral T-cell Lymphomas (PTCL)

Start date: 2021-03-01
Primary completion: 2023-09-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.